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DN200428 is a new compound designed and synthesized to treat 
osteoporosis as a cathepsin K inhibitor. Its poor aqueous solubility is expected to 
result in low bioavailability after oral administration. The objective of this study is 
to formulate self-microemulsifying drug delivery systems (SMEDDS) for 
enhancing the oral bioavailability of DN200428. Solubility studies of DN200428 
were performed to select the suitable oil, surfactant and cosurfactant. Pseudoternary 
phase diagrams were plotted to identify the microemulsion region and to determine 
the range of components in isotropic mixture. The D-optimal mixture design and 
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the desirability function was introduced to optimize the formulation of SMEDDS 
with the optimum physicochemical characteristics, i.e., high drug concentration at 
15 minutes after dilution in simulated gastric fluid (SGF) and high solubilized 
capacity. Pharmacokinetic study was performed in rats, and the drug concentration 
in plasma samples was assayed using the high-performance liquid chromatography 
with fluorescence detector (HPLC-FL). The optimized DN200428-loaded 
SMEDDS formulation consisted of 5.0% of Capmul MCM EP (oil), 75.0% of 
Tween 20 (surfactant) and 20.0% of Carbitol (co-surfactant). The droplet size of 
microemulsion formed by the optimized formulation was 10.7 ± 1.6 nm. 
Transmission electron microscopy (TEM) analysis was confirmed the spherical 
shape of the microemulsion. Pharmacokinetic studies showed that the relative oral 
bioavailability of DN2000428-loaded SMEDDS increased up to 3-fold when 
compared with its solution in DMSO:PEG400 (8:92). Thus, it can be concluded 
that the formulation of SMEDDS could be a promising approach to improve oral 
bioavailability of DN200428. 
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In recent years, poor drug solubility in water issue has been wide spread as 
emerging of the new drug candidates from the latest drug design tends to have 
hydrophobic properties and low bioavailability (Sandeep and Vijaykumar, 2015). 
The solubility and/or dissolution rate in the gastrointestinal (GI) tract is the main 
reason for the limitation of the absorption of these drugs. Several techniques were 
developed to improve the absorption of poorly water-soluble drug by enhancing the 
solubility of the compound including pH modification, salt formation, using of co-
solvent, nanosuspensions, polymeric nanoparticles, solid dispersions, cyclodextrin 
complexes, and lipid-based formulation such as proliposome and self-emulsifying 
drug delivery system (Sandeep and Vijaykumar, 2015; Yeom et al. 2015). 
Self-Microemulsifying Drug Delivery System (SMEDDS) has been 
successfully used as a promising strategy to enhance oral bioavailability for several 
poor aqueous soluble compounds (Kamboj and Rana, 2016; Yeom et al., 2015; 
Zhang et al., 2007). Many commercial products of SMEDDS preparation are 
available on the market in capsules such as Neoral® (Cyclosporine A) Fortovase® 
(Saquinavir), and Agenerase® (amprenavir) (Porter et al., 2008). SMEDDS is an 
isotropric mixture of oil, surfactant and co-surfactant, which can spontaneous form 
fine oil-in-water (o/w) emulsions after dilution in the GI fluid with the gentle 
agitation from GI tract motility. Spontaneous formation of the microemulsion in the 
GI tract influence the drug to maintain in solubilized form. The small droplet size 
also provides a large interfacial surface area which promotes rapid drug release, 
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consequently, enhance the drug absorption by transporting the drug through the 
unstirred water layer to the GI membrane. In addition, one of the SMEDDS 
advantage as lipid-based formulation is this delivery system can avoid the hepatic 
first-pass effect by its uptake via the lymphatic transport (Wu et al., 2015; Zhang et 
al., 2008). There are many studies demonstrated that enhanced drug release from 
SMEDDS could improve the bioavailability (Wu et al., 2015; Yeom et al., 2015, 
Zhang et al., 2007). 
DN200428 is a new compound designed and synthesized to treat 
osteoporosis as a cathepsin K inhibitor. Osteoporosis is a bone disease characterized 
by low bone mass with a consequent increase in bone fragility and risky of broken 
bone (Stoch and Wagner, 2008). Osteoporosis could be prevented or treated by 
either inhibiting bone resorption and/or increasing bone formation. Cathepsin K is 
the cysteine protease expressed in the osteoclast and has a critical role in 
osteoclastic bone resorption (Boonen et al., 2012; Stoch and Wagner, 2008). 
Therefore, Cathepsin K inhibitors were expected to be novel target for developing 
new drug candidates to treat osteoporosis by direct inhibition of the enzyme 
cathepsin K which is primarily responsible for bone matrix degradation by 
osteoclasts (Boonen et al., 2012). Like several new drug candidates, DN200428 is 
practically insoluble in water. Also, its poor aqueous solubility is expected to result 
in low bioavailability after oral administration. To improve the solubility, SMEDDS 
was applied to the formulation of DN200428. 
Design of experiment (DOE) is a systemic experimental approach used for 
identification of the correlation between independence variables (input variables) 
and dependence variables (responses) according to the statistics. The advantage of 
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DOE is fewer experiments were performed to achieve the optimum formulation. 
The mathematical models were involved and the precise estimates of each response 
were calculated based on the polynomial equations without doing experiment 
(Singh et al., 2011). The magnitude of the coefficients also demonstrates 
significance of each independent variable to each dependent variable (Kamboj and 
Rana, 2016). Due to time-consuming of development process based on the trial and 
error, many experimental designs have been used for optimization of SMEDDS 
such as Box-Behnken design, factorial design and D-optimal mixture design. (Chaji 
and Lodha, 2008; Cho et al., 2013; Holm et al., 2006; Kamboj and Rana, 2016; 
Yeom et al., 2015). Unlike other design, D-optimal mixture design considered total 
mixture as 100% which is suitable for development of SMEDDS (Yeom et al. 
2015). 
The aim of this study was to develop and optimize DN200428-loaded 
SMEDDS formulation by using the D-optimal mixture design to improve its oral 
bioavailability.  
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DN200428 was supplied by Hanlim Pharmaceutical Co., Ltd. (Seoul, South Korea). 
Etodolac was purchased from Tokyo Chemical Industry (Tokyo, Japan). Capmul 
MCM EP (Glyceryl caprylate/caprate) was gifted from Abitec. (Wisconsin, United 
States). Capryol 90 (Propylene glycol monocaprylate), Labrafil M1944 CS (Oleoyl 
polyoxyl-6 glycerides), Labrafil M2125 CS (Linoleoyl polyosyl-6 glycerides), 
Labrafil M2130 CS (Lauroyl polyoxyl-6 glycerides), and Labrasol (Caprylocaproyl 
polyoxyl-8 glycerides) were purchased from Gattefossé (Saint Priest, France). 
Cotton seed oil, Soybean oil, Sunflower seed oil, Tween 20, Tween 80, Polyethylene 
glycol 400 (PEG400), Solutol HS 15 (Poly-oxyethylene esters of 12-hydroxystearic 
acid), Carbitol (Diethylene glycol ethyl ether) and Span 80 (Sorbitan monooleate) 
were purchased from Sigma Aldrich (St. Louis, MO, USA). All other chemicals and 




2.2.1 Solubility studies 
 
The solubility of DN200428 was determined in various natural oils (Cotton seed 
oil, Sunflower seed oil, Soybean oil), synthetic/semi synthetic oils (Capmul MCM 
EP, Labrafil 1944 CS, Labrail M2125 CS, Labrafil M2130 CS, Ethyl oleate), and in 
various surfactants/co-surfactant (Tween 20, Tween 80, PEG 400, Labrasol, Solutol 
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HS 15, Carbitol, Span 80). The excess amount of DN200428 were added into 1 mL 
of each oil/surfactant and vortexed until the drug was totally dispersed. The samples 
were kept at a constant temperature in shaking water bath (Lab Companion, BS-21, 
JEIO TECH) at 50 rpm and 37±0.5°C for 24 hours. Then, the samples were 
centrifuge (Centrifuge 5415 R, Eppendorf, Germany) at 13200 rpm for 5 minutes. 
The supernatants were collected and filtered through 0.45 µm syringe filter 
(Minisart®-RC, Sartorius, Germany). The filtrates were analyzed by HPLC-FL after 
appropriate dilution with dimethyl sulfoxide (DMSO): acetonitrile (ACN) (50:50 
v/v). 
 
2.2.2 HPLC analysis of DN200428 
 
Quantification of DN200428 was validated on high-performance liquid 
chromatography (HPLC) system. The samples obtained from solubility, dilution 
test, solubilized capacity, and in vivo animal pharmacokinetic study were 
determined for DN200428 concentration using an isocratic HPLC system. The 
HPLC system included a pump (We2695; Waters Corporation, Milford, MA, USA), 
fluorescence detector (W2475; Waters Corporation, Milford, MA, USA), and 
chromatographic XBridge Shield RP18 column (4.6×250 mm, 5 µm; Waters 
Corporation, Milford, MA, USA) that was maintained at a flow rate of 1.0 mL per 
minute at 25°C. The solvent consists of ACN and water (65:35 v/v) was used as 
mobile phase for in vitro studies. Whereas ACN:10mM phosphate buffer pH 2.5 
(57:43 v/v) was used as mobile phase for in vivo studies. The combination of 
DMSO and ACN (50:50 v/v) was used as diluting solvent. For fluorescence 
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detection, the excitation and emission wavelengths of DN200428 were set at 295 
and 395 nm, respectively. And the excitation and emission wavelengths of etodolac 
as an internal standard were set at 235 and 345 nm, respectively. The injection 
volume was 20 µL. The chromatograms were evaluated with Empower 2 Software 
(Waters Corporation, Milford, MA, USA) 
 
2.2.3 Construction of pseudoternary phase diagram 
 
Based on the solubility and hydrophilic-lipophilic balance (HLB) value, Capmul 
MCM EP, Tween 20 and Carbitol were chosen as oil, surfactant and co-surfactant, 
respectively. To determine the microemulsion existence area, pseudoternary phase 
diagrams were constructed employing the water titration method at 37 °C. Mixtures 
of surfactant and co-surfactant (S-mix) in different ratios by volume (3:1, 2:1, 1:1, 
1:2, 1:3) were prepared. Each ratio of S-mix was combined with oil in different 
ratios of 1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 8:2 and 9:1 with a total volume of 1 mL. 
The prepared mixtures were vortexed and then titrated with water dropwise under 
gentle agitation by magnetic stirrer (75 rpm) up to 100 mL (1:100 dilution). After 
each addition, the emulsion was observed visually (turbid or clear). Each 
experimental component of blank SMEDDS were marked as opened circles 
(microemulsion; clear) and closed circles (macroemulsion; turbid).  The 
microemulsion region was figured out by constructing a pseudoternary phase 
diagram using the Sigma Plot® software (Sigma Plot, USA). Additional point of 
blank SMEDDS were performed to fulfill the appropriate region to select the design 
space. 
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2.2.4 Preparation of DN200428 suspension, solution and 
SMEDDS formulation 
 
DN200428 suspension (2.5 mg/mL) was prepared by dispersing the drug in 
PEG400 (1.0%) and then water was added. The suspension was vortexed to make 
homogenous mixture. DN200428 solution in DMSO:PEG400 (8:92) (2.5 mg/mL) 
was prepared by dissolving the drug in DMSO and then added  PEG400 into the 
mixture. The solution was vortexed and stirred at the room temperature for 1 hour. 
A blank SMEDDS formulation was prepared by mixing oil, surfactant, and 
cosurfactant. And DN200428 was added into blank SMEDDS to make 2.5 mg/mL 
DN200428-loaded SMEDDS. Then the mixture was vortexed until the drug was 
totally dispersed. The mixtures were kept at a constant temperature in shaking water 
bath at 50 rpm and 37±0.5°C for 3 hours to obtain a clear homogenous solution.  
 
2.2.5 Optimization of DN200428-loaded SMEDDS 
formulations using D-optimal mixture design 
 
Amount of oil, surfactant and co-surfactant were chosen as the independent 
variables based on the solubility and the ability of the previously prepared 
pseudoternary phase diagram to form microemulsion. Range of Capmul MCM EP 
(oil; X1), Tween 20 (surfactant; X2), and Carbitol (co-surfactant; X3) using in the 
design were set as 5-15%, 55-75%, and 15-35%, respectively. The total combination 
of each formulations was 100%. Drug concentration at 15 minutes after diluted 
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with simulated gastric fluid (SGF) (1:250 dilution) (DIL; Y1), and solubilized 
capacity (SC; Y2) were evaluated to determine the optimal SMEDDS formulation 
for best physiochemical characteristics. Design Expert® Software version 7 (Stat-
Ease Inc, Minneapolis, MN, USA) was used for developing and evaluating the 
experimental design. Sixteen formulations were obtained from the program to fit a 
cubic model, to check for lack of fit, and to estimate experimental error in the 
responses. The responses were fitted in the linear, quadratic, cubic and special cubic 
polynomial model. The equations were generated for each response using the 
software. The suitable mathematical fitting model was selected based on the 
comparison of various statistical parameters provided by the analysis of variance 
(ANOVA) such as sequential p-value, lack of fit p-value, r-squared and adequate 
precision. The selected model for each response were used for predicting the 
desirable results of the optimized independent factors by using the desirability 
function. 
 
2.2.6 In vitro evaluation and optimization of SMEDDS 
formulation 
 
Droplet size (DS) and polydispersity index (PDI) 
 
Aliquot (20 µL) of DN200428-loaded SMEDDS formulation was reconstituted 
with 1000 mL double-distilled water. After gently shaking, microemulsions were 
transferred into optical polystyrene cuvette and were measured the DS and PDI by 
Zeta-potential & Particle size Analyzer (Photal, ELSZ, Otsuka Electronic, Japan) 
 
- 9 - 
  
Drug concentration at 15 min after diluted with SGF (1:250 dilution) 
(DIL) 
 
Aliquot (100 µL) of DN200428-loaded SMEDDS formulation was added into 25 
mL of SGF in a constant temperature at 37°C and gently stirred at 75 rpm with 
magnetic stirrer for 15 minutes. Samples 1 mL were collected and filtered through 
0.2 µm membrane filtration. The filtrate was centrifuged at 13200 rpm for 2 
minutes. The supernatant was collected and diluted with diluting solvent, after 
which 100 µL of the sample was analyzed. SGF in this study was prepared by 
dissolving 2.0 g of sodium chloride in 7.0 mL of hydrochloric acid and adjusted the 
volume to 1000 mL with water according to the method in United States 
Pharmacopoeia (USP), 39th edition without addition of the purified pepsin. 
 
Solubilized capacity (SC) 
 
Blank SMEDDS of each formulation was prepared by mixing Capmul MCM EP, 
Tween 20, Carbitol. The excess amount of DN200428 was added into 1 mL of 
blank SMEDDS and vortexed until the drug was totally dispersed. The samples 
were kept at a constant temperature in shaking water bath at 50 rpm and 37±0.5°C 
for 24 hours. Then, the samples were centrifuge at 13200 rpm for 10 minutes. The 
supernatants were collected and filtered through 0.45 µm syringe filter (Minisart®-
RC, Sartorius, Germany). The filtrates were analyzed by HPLC-FL after appropriate 
dilution with DMSO:ACN (50:50 v/v). 
 
 
- 10 - 
  
Morphology of microemulsion 
 
The morphology of the microemulsion droplet formed from optimized SMEDDS 
formulation was observed using energy-filtering transmission electron microscope 
(TEM; LIBRA 120; Carl Zeiss, Jena, Germany) at 80 kV. 20 µL of SMEDDS 
formulation was added into 1000 µL of water (1:50 dilution) and sample drop was 
placed on a copper grid. The sample was subsequently stained with uranyl acetate 
solution for 10 seconds and washed with water for 1 second for two times. The 
excess was drawn off with a filter paper. 
 
2.2.7 In vivo studies 
 
Oral administration and plasma collection 
 
The bioavailability of DN200428 solution and DN200428-loaded SMEDDS were 
assessed in rats. The animal experiments were performed in accordance with the 
National Institute of Health guidelines on principles of laboratory animal care 
(National Institute of Health publication 85-23, revised 1996) and were approved 
by the Institutional Animal Care and Use Committee of the College of Pharmacy, 
Seoul National University, Seoul, Korea. Male Sprague-Dawley rats (weight 300 g, 
age 7-9 weeks) were purchased from Orient Bio (Kyunggi-Do, Korea). The rats 
were fasted for approximately 12 hours with free access to water before experiment. 
The DN200428 solution and DN200428-loaded SMEDDS optimized formulation 
were administered at doses of 5 mg/kg with or without 1 mL of water after 
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administration. Blood samples (approximately 300 µL) were collected from the 
cannulated femoral artery at predetermined time intervals after oral administration 
into polyethylene micro test tube. The samples were immediately centrifuged at 
13200 rpm and 4°C for 3 minutes. The supernatants (100 µL) were collected and 
stored at -20°C until further analysis. 
 
Analysis of plasma drug concentration 
 
The plasma samples (100 µL) were mixed with 1 mL of internal standard (Etodolac, 
400 ng/mL in acetonitrile). Each sample was shaken for 5 minutes to completely 
dissolve the drug in acetonitrile and centrifuged at 13200 rpm and 4°C for 5 
minutes. The supernatant was collected and evaporated to remove organic solvent 
under nitrogen gas on a pressured gas blowing concentrator (EYELA, MGS-2200, 
Tokyo Rikakikai, Japan). The residue was reconstituted with 100 µL of 
DMSO:ACN (10:90) and vortexed for 5 min. The concentration of DN200428 was 
determined by HPLC-FL as described above. The calibration curve of DN200428 
concentration in plasma was prepared by spiking the known amount of drug into 
blank plasma. The curve was linear (R2 = 0.9998) over the range of 40-2000 ng/mL 
Area of DN200428 peak for 40 ng/mL was approximately 65000 and was identified 










The plasma concentration data were analyzed by an noncompartmental model using 
WinNonlin (version 5.0.1, Pharsight, CA, USA) to obtain pharmacokinetic 
parameters. The area under the plasma concentration versus time curve from zero 
to 5 hours (AUC0-5) was calculated using trapezoidal method. The maximum 
plasma concentration (Cmax) and the time to reach Cmax (Tmax) were obtained from 
the plasma data .  The s ignif icance differences observed for  the mean 
pharmacokinetic parameters after oral administration of DN200428 formulations to 
rats was determined using analysis of variance (ANOVA) at a significance level of 
P < 0.05 and P < 0.01. Tukey multiple comparisons was used as subsequent 
analysis by Graphpad PRISM® Software (Version 5.01). Results are presented as 
mean values ± standard deviation (SD). 
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3. Results and Discussion 
 
Selection of oil, surfactant and co-surfactant 
 
Solubilization of drug in the excipients using in SMEDDS formulation is an 
important determination for developing of microemulsion. The materials showing 
high solubility of DN200428 should be selected. Solubility of DN200428 in 
excipients were shown in the Table 1. Among several types of oil, Capmul MCM 
EP showed the maximum solubility (0.239±0.04 mg/mL). Tween 20 and Carbitol 
showed the highest solubility among surfactant and co-surfactant of 7.461±0.76 
mg/mL and 6.563±0.11 mg/mL, respectively. In addition, hydrophilic-lipophilic 
balance (HLB) values of surfactant was considered to use as a tool for categorizing 
between surfactant and co-surfactant. The water-soluble surfactant which has HLB 
values greater than 12 are recommended to use in SMEDDS formulation due to 
theirs easy forming micelle properties (Dokania and Joshi, 2015; Pouton and Porter, 
2008). Also, surfactants with low HLB value can reduce the interfacial tension of 
the film formed by emulsion droplets and ensures the flexible of the film. In 
addition, combination of low HLB (HLB <10) and high HLB (HLB > 10) surfactant 
can prolonged the stability of the formulation. To form oil in water emulsion, the 
main emulsifier in SMEDDS should be water-soluble surfactant which has higher 
HLB. Thus, Capmul MCM EP, Tween 20 (HLB = 16.7) and Carbitol (HLB =4.2) 
were selected as oil, surfactant and co-surfactant in this study. The combination was 
further evaluated using pseudoternary phase diagram. 
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Construction of pseudoternary phase diagram 
 
The selected oil, surfactant and co-surfactant were investigated to confirm the 
microemulsion was formed by the mixture. Pseudoternary phase diagrams were 
plotted from Capmul MCM EP (oil), Tween 20 (surfactant), and Carbitol (co-
surfactant) as shown in Figure 1. Capmul MCM EP, Tween 20, and Carbitol were 
marked as 100% at the apex of the diagram. Only three combinations of various 
ratios of S-mix and oil (marked as opened circle) showed the ability to form 
microemulsion among the experimental blank SMEDDS when diluted with water 
up to 100 times. However, the other combination of mixture showed turbid 
emulsion after diluted with water not more than 20 times (marked as closed circle). 
Six blank SMEDDS in different ratios were further performed to cover the previous 
three spots. The microemulsion region was shown in the light gray region as in 
Figure 1. This result was confirmed that concentration of oil using in SMEDDS is 
typically less than 20% (Dokania and Joshi, 2015). 
 
Statistical analysis using the D-optimal mixture design of 
DN200428-loaded SMEDDS 
 
Design of experiment was introduced in development of SMEDDS in this study. 
Unlike other design, D-optimal design was applied in this study and optimized the 
SMEDDS formulation as it considered the system as 100 percent (Holm et al, 2006; 
Yeom et al, 2015). From the microemulsion region, the design space for D-optimal 
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mixture design of this study was selected as dark gray region as shown in Figure 1. 
The amount of oil, surfactant and co-surfactant were identified as the factors which 
influences the droplet size and in vitro dispersion of SMEDDS formulations 
(Kamboj and Rana, 2016; Yeom et al., 2015). Thus, these factors were set as the 
i npu t  va r i ab l e s .  Droplet size and the size distribution are the most important 
characteristics affecting the in vivo test of emulsions (Liu et al., 2009). The rate and 
drug release depends on the size of emulsion droplet. Smaller droplet size and larger 
surface area is easier for drug absorption. However, the average microemulsion 
droplet size and polydispersity index after dilute DN200428-loaded SMEDDS with 
water (1:50 dilution) of the experimental formulations were small (10.3-11.9 nm) 
and homogenize (0.010-0.144) as shown in the Appendix Table I. In addition, no 
models were fitted to both responses indicating no significantly difference between 
all formulations. Thus, these two parameters were not included in this design. Table 
2 shows the range independent variables and goal of dependent variables using in 
D-optimal design of this study. The results obtained from the various SMEDDS 
formulations and dependent variable of D-optimal mixture design are shown in 
Table 3. The results were inputted to Design Expert® 7 Software. The data were 
statistically fitted to different models and their polynomial equations of the 
responses were generated (drug concentration at 15 minutes after diluted with 
simulated gastric fluid (SGF) (1:250 dilution) (DIL; Y1), and solubilized capacity 
(SC; Y2)). The coefficients of X1, X2, X3 were statistically correlated the response. 
A positive sign of coefficient represents a synergistic effect whereas a negative sign 
represents an antagonistic effect of the coefficients. The higher coefficient means 
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the independent variable has larger influence on the response. The model results 
statistic data are shown in Table 4. 
 
Drug concentration at 15 minutes after diluted with SGF (1:250 dilution) 
(DIL; Y1) 
 
Drug precipitation is one of the problem found during the dispersion and digestion 
of lipid based formulation which may reduce the drug absorption and decreased the 
oral bioavailability (Khan et al., 2016). The drug concentration at 15 minutes after 
diluted 250 times with SGF represents the ability to maintain microemulsion 
formed by SMEDDS formulation. As shown in Table 3, formulation 7 showed the 
highest drug concentration (2.155 ± 0.11 µg/mL) and formulation 11 showed the 
l owes t  d rug  concen t ra t ion  (1.402 ± 0.10 µg/mL). The data were fitted to the 
quadratic model. The statistical fitting of model and ANOVA statistical results are 
shown in Table 4 and Table 5. The equation (1) was obtained from the program for 
DIL (Y3); 
 
DIL (Y1) = +1.80 X1 + 2.47 X2 + 1.52 X3 − 1.57 X1X2 − 0.84 X1X3 −
0.66 X2X3         (1) 
 
Based on the equation, the coefficients indicate the influential of the response. The 
magnitude of the coefficient was in the order X2 > X1 > X3. The coefficients of X2 
had the most significantly high magnitude, indicating that amount of Tween 20 (X2) 
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was a critical factor that affected Y1. Although X2 had a positive effect on Y1, 
coefficients of combination of the independent variables (X1X2, X1X3, and X2X3) 
shows a negative effect on Y1, suggesting the inverse relationship between X2 and 
other parameters. A higher amount of X2 resulted in higher Y1. In other words, risk 
of precipitation was decreased with an increased in Tween 20 content. 
 
Solubilized capacity (SC; Y2) 
 
The solubilized capacity of each formulation was shown in Table 3. The data were 
fitted to the linear model.  The statistical fitting of model and ANOVA statistical 
results are shown in Table 4 and Table 5. The correlation between solubilized 
capacity and independent variables is shown in equation (2). 
 
SC (Y2) = +2.47 X1 + 6.36 X2 + 6.86 X3    (2) 
 
Solubilized capacity is related to the ability to maintain the solubilized form of drug 
by SMEDDS formulation. The higher SC was expected to result in high drug 
absorption. The magnitude of the coefficient was in the order X3 > X2 > X1. The 
positive sign of all coefficients indicated that solubilized capacity of DN200428 is 
higher as increasing the content of oil or surfactant or co-surfactant. However, the 
content of surfactant and co-surfactant may be mainly responsible for the 
solubilized capacity of the SMEDDS when compared to oil, which corresponding 
to the solubility of DN200428 in excipient from Table 1. 
 
- 18 - 
Optimized SMEDDS formulation 
Desirability function of the Design Expert® program was used for optimization of 
all the responses. Y1 and Y2 were set to be maximized. After calculating by the 
combination of all the polynomial equations mentioned above, the program 
suggested the independent variables of 5.0% of Capmul MCM EP (oil), 75.0% of 
Tween 20 (surfactant) and 20.0% of Carbitol (co-surfactant) as the optimized 
formulation with desirability of 0.878.  The droplet size and polydispersity index of 
the optimized formulation is small (10.7 ± 1.6 nm) and homogenize (0.006 ± 0.0). 
The optimized independent variables and the predicted responses are presented in 
Table 6. The percentage prediction error of Y1 and Y2 were similar to the predicted 
values, suggesting that the D-optimal design is suitable for optimizing the 
SMEDDS formulations. The TEM image of the optimized SMEDDS formulation 
showed the spherical shape of emulsion droplets which comprised with the 
measured droplet size as in Figure 6. 
In vivo pharmacokinetic studies in Rats 
The plasma concentration-time profiles of DN200428 after oral administration (5 
mg/kg) in rats are presented in Figure 7. The plasma concentrations of DN200428 in 
rats after administration of the optimized SMEDDS were significantly higher than 
those in rats receiving the DN200428 solution (DMSO:PEG400 (8:92) solution) and 
DN200428 suspension (data not shown). The pharmacokinetic parameters are listed 
in Table 7. Time to reach maximum plasma concentration (Tmax) of the optimized 
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SMEDDS (with water) was significantly higher than those of the solution with and 
without giving water after administration. The delayed of Tmax may resulted from 
time to form microemultion of SMEDDS before drug absorption. However, the 
maximum plasma concentration (Cmax) were identical for the DN200428 solution 
with/without water and the optimized SMEDDS with/without water. Nevertheless, 
the optimized SMEDDS formulation (without water) showed significantly higher 
AUC values than the solution (with water) (3.23-fold higher value; P < 0.01). Also, 
the optimized SMEDDS (with water) showed significantly higher AUC values than 
the solution (with and without water) (3.87-fold; P < 0.01 and 2.05-fold; P < 0.05 
and, respectively). Increasing of AUC could be ascribed to the improvement in 
solubility and dissolution rate of DN200428 by the optimized SMEDDS. The oral 
bioavailability of DN200428 in optimized SMEDDS formulation was significantly 
higher than that of in the solution with and without water after administration. Oral 
bioavailability of DN200428 in the optimized SMEDDS (without water) was 
increased 1.63-fold and 2.85-fold compared to that of the solution (without water) 
and solution (with water), respectively. In addition, oral bioavailability of 
DN200428 in the optimized SMEDDS (with water) was increased 1.84-fold and 
3.22-fold compared to that of the solution (without water) and solution (with water), 
respectively. From the plasma profiles, the solution with and without water were 
eliminated faster than the optimized SMEDDS, which could be attributed to the 
precipitation rate of DN200428. SMEDDS was designed to maintain the solubilized 
form of the drug for enhancement of drug absorption. Although the Tmax of the 
solutions were shorter than those of the optimized SMEDDS indicating faster 
absorption of DN200428 in the solutions, the precipitation rate of the solutions are 
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faster than the optimized SMEDDS. Moreover, plasma concentration of DN200428 
suspension in all time point were lower than the LLOQ, which suggesting that the 
compound has low absorption in powder form (data not shown). Therefore, the 
optimized SMEDDS formulation developed in this study was effective in enhancing 









Optimized DN200428-loaded SMEDDS formulation was successfully developed by 
using the desirability of D-optimal mixture design. The optimized SMEDDS 
formulation consisting of Capmul MCM EP (5.0%), Tween 20 (75.0%), and Carbitol 
(20.0%) showed small homogenous droplets in spherical shape of microemulsion 
after dilution, and had good solvent properties to maintain DN200428 in solubilized 
form before absorption. In addition, the desirable in vitro experimental responses of 
the formulation also close to the predicted value. Moreover, the in vivo 
pharmacokinetic studies showed higher bioavailability for optimized SMEDDS 
formulation than the solution. Thus, this study demonstrates that SMEDDS is a 
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Table 1 Solubility of DN200428 in selected excipients 
Excipient Solubility (mg/mL) 
Oil  
Capmul MCM EP 0.239±0.04 
Capryol 90 0.191±0.01 
Labrafil M2130 CS 0.136±0.00 
Labrafil M2125 CS 0.097±0.00 
Labrafil M1944 CS 0.054±0.00 
Cotton seed oil 0.004±0.00 
Soybean oil 0.004±0.00 
Sunflower seed oil 0.002±0.00 
Ethyl oleate 0.002±0.00 
Surfactant  
Tween 20 7.461±0.76 
PEG400 5.022±0.20 
Labrasol 3.306±0.20 
Tween 80 2.284±0.13 
Solutol HS 15 1.860±0.98 
Co-surfactant  
Carbitol 6.563±0.11 
Span 80 0.015±0.01 
Note: Values are presented as the mean ± SD (n=3) 
  
- 26 - 




X1 : Amount of oil (Capmul MCM EP) 5 15 
X2 : Surfactant (Tween 20)  55 75 
X3 : Co-surfactant (Carbitol)  15 35 
Dependent variables Goal 
Y1 : Drug concentration at 15 min after diluted with SGF (1:250 
dilution) (µg/mL; DIL) Maximize 
Y2 : Solubilized capacity (mg/mL; SC)  Maximize 
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Table 3 Composition and observed responses from randomized runs in the D-












tol DIL SC 
(%; X1) (%; X2) (%; X3) (µg/mL; Y1) (mg/mL; Y2) 
1 5 65 30 1.799 ± 0.01 6.763 ± 0.04 
2 5 70 25 1.893 ± 0.07 6.427 ± 0.07 
3 5 75 20 2.142 ± 0.10 6.229 ± 0.05 
4 5 75 20 2.195 ± 0.11 6.671 ± 0.06 
5 5 60 35 1.576 ± 0.05 6.906 ± 0.10 
6 5 60 35 1.620 ± 0.02 6.671 ± 0.11 
7 10 75 15 2.155 ± 0.11 5.655 ± 0.04 
8 10 75 15 2.048 ± 0.14 5.527 ± 0.11 
9 10 65 25 1.610 ± 0.08 5.736 ± 0.07 
10 10 60 30 1.531 ± 0.01 5.893 ± 0.10 
11 15 55 30 1.402 ± 0.10 5.037 ± 0.04 
12 15 55 30 1.419 ± 0.10 5.058 ± 0.06 
13 15 60 25 1.613 ± 0.06 4.985 ± 0.02 
14 15 65 20 1.597 ± 0.07 5.018 ± 0.05 
15 15 70 15 1.819 ± 0.06 4.754 ± 0.01 
16 15 70 15 1.808 ± 0.08 4.868 ± 0.02 
Notes: DIL, Drug Concentration at 15 min after diluted (1:250 dilution) in SGF; 
SC, Solubilized capacity 
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Table 4 Summary of statistical analyses and model equations for the measured responses 
Response Model Sequential
p-value 
Lack of fit 
p-value 









DIL (Y1) Quadratic 0.0487 0.1596 0.06 3.10 0.69 0.9708 0.9561 0.9327 22.120 
SC (Y2) Linear < 0.0001 0.9660 0.12 2.11 0.30 0.9779 0.9745 0.9652 37.055 
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Table 5 Analysis of variance of measured responses 
Response Source Sum of squares df Mean square F-value P-value prob. > F Remark 
DIL (Y1) Model 0.99 5 0.20 66.39 < 0.0001 Significant 
Linear mixture 0.96 2 0.48 160.36 < 0.0001 
X1X2 0.010 1 0.010 3.40 0.0952 
X1X3 2.88 × 10-3 1 2.88 × 10-3 0.97 0.3490 
X2X3 0.015 1 0.015 4.90 0.0513 
Residual 0.030 10 2.982 × 10-3 
Lack of Fit 0.022 5 4.304 × 10-3 2.59 0.1596 Not significant 
Pure Error 8.302 × 10-3 5 1.660 × 10-3 
Corrected total 1.02 15 
SC (Y2) Model 8.51 2 4.25 287.41 < 0.0001 Significant 
Linear Mixture 8.51 2 4.25 287.41 < 0.0001 
Residual 0.19 13 0.015 
Lack of Fit 0.052 8 6.530 × 10-3 0.23 0.9660 Not significant 
Pure Error 0.14 5 0.028 
Corrected total 8.70 15 
Note: df, degrees of freedom
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Table 6 Predicted and experimental results of optimized DN200428-loaded 
SMEDDS formulation 
Response Predicted value Experimental value 
Prediction 
error (%) 
DIL (µg/mL; Y1) 2.17 2.34 ± 0.21 - 7.83 
SC (mg/mL; Y2) 6.462 6.164 ± 0.06 4.61 
Note: Prediction error (%) was calculated using the formula ([predicted value – 
experimental value]/predicted value) × 100; values are presented as the mean ± SD 
(n=3) 
- 31 - 
Table 7 Pharmacokinetic parameters of DN200428 after oral administration of the solution and optimized SMEDDS formulation in rats. 







Cmax (ng/mL) 122.20 ± 38.80 108.13 ± 18.53 164.27 ± 55.87 162.99 ± 14.00 
Tmax (min) 33.75 ± 7.50 33.75 ± 7.50 45.00 ± 0.00 63.75 ± 18.87a,b 
AUClast 
(ng·min/mL) 
11044.56 ± 1765.64 5849.48 ± 2452.40 18868.64 ± 7944.91b 22637.40 ± 3668.47b,c 
AUCinf 
(ng·min/mL) 
15826.89 ± 2363.08 9043.41 ± 2651.75 25782.23 ± 9610.42b 29087.39 ± 4946.50b,c 
t1/2 (min) 79.80 ± 33.74 43.42 ± 12.56 110.76 ± 64.75 86.33 ± 19.21 
BA (%) 6.78 3.87 11.04 12.46 
Note: AUC, area under the curve; SMEDDS, Self-Microemulsifying Drug Delivery System. The data are presented as mean ± SD (n=4) 
a P < 0.01 when compared with the parameter of solution (without water) 
b P < 0.01 when compared with the parameter of solution (with water) 
c P < 0.05 when compared with the parameter of solution (without water) 
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Figure 1 Pseudoternary phase diagram of Capmul MCM EP (oil), Tween 20 
(surfactant), and Carbitol (co-surfactant) and design space for D-optimal mixture 
design 
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Figure 2 Contour and response surface plots for DIL and SC 
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Figure 3 Contour and response surface plots of numerical optimization of DN200428-loaded SMEDDS using desirability approach 
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Figure 4 Droplet size distribution and TEM image of reconstituted numerically 
optimized DN200428-loaded SMEDDS formulation in water (1:50 dilution) 
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(a) 
(b) 
Figure 5 In vivo pharmacokinetic profiles after oral administration of (a) the 
DN200428 solution (without water) (●) and the optimized DN200428-SMEDDS 
(without water) (○) (b) the DN200428 solution (with water) (■) and the optimized 
DN200428-SMEDDS (with water) (□)  
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Appendix 
Table I Droplet size and polydispersity index results from randomized runs in the 














(%; X1) (%; X2) (%; X3) (nm) 
1 5 65 30 12.2 ± 0.8 0.144 ± 0.2 
2 5 70 25 10.7 ± 6.2 0.039 ± 0.0 
3 5 75 20 13.3 ± 2.2 0.060 ± 0.1 
4 5 75 20 11.9 ± 2.9 0.031 ± 0.1 
5 5 60 35 13.9 ± 2.6 0.013 ± 0.1 
6 5 60 35 12.7 ± 5.5 0.102 ± 0.1 
7 10 75 15 12.6 ± 1.3 0.161 ± 0.1 
8 10 75 15 11.6 ± 2.1 0.020 ± 0.0 
9 10 65 25 12.7 ± 1.6 0.010 ± 0.0 
10 10 60 30 10.3 ± 0.1 0.104 ± 0.0 
11 15 55 30 12.8 ± 1.9 0.080 ± 0.0 
12 15 55 30 13.4 ± 0.9 0.127 ± 0.1 
13 15 60 25 12.0 ± 0.2 0.119 ± 0.0 
14 15 65 20 12.2 ± 1.1 0.022 ± 0.0 
15 15 70 15 11.7 ± 0.8 0.078 ± 0.0 
16 15 70 15 11.7 ± 0.5 0.016 ± 0.0 
Notes: DS, Droplet size; PDI, Polydispersity index 
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국 문 초 록 
DN200428 은 Cathepsin K 억제 기전으로 골다공증을 치료하기 
위해서 설계한 신약후보 물질이다. 그러나, 낮은 용해도 문제로 인해 경구 
생체 이용률이 매우 낮을 것으로 예상된다. 본 연구의 목적은 DN200428 의 
Self-Microemulsifying Drug Delivery System (SMEDDS) 제형화를 
통해 생체 이용률을 개선하는 것이다. 적합한 오일, 계면활성제 및 보조 
계면활성제를 선정하기 위해 DN200428 의 용해도 연구를 수행하였으며, 
마이크로에멀젼이 형성되는 범위를 알아내고 등장 혼합물에서 성분들의 
범위를 결정하기 위해 위상 3 상 상평형도를 작성하였다. 또한 최적의 
물리화학적 특성들을 갖는 SMEDDS 제형을 결정하기 위해 D-Optimal 
mixture design 과 기대함수 (Desirability function)를 도입하였다. 즉, 
인공 장액에서 15 분간 희석한 후의 최고 약물 농도와 high solubilized 
capacity 등을 측정하였다. 체내 약물동태학적 연구는 랫트에서 
수행하였으며, 고성능 형광 검출-액체 크로마토그래피 (HPLC-
fluorescence)를 사용하여 혈중 약물의 농도를 측정하였다. 최적화된 
DN200428 이 봉입된 SMEDDS 제형은 5.0%의 Capmul MCM EP (오일), 
75.0%의 Tween 20 (계면활성제) 그리고 20.0%의 Carbitol (보조 
계면활성제)로 구성되었다. 최적화된 제형에서 마이크로에멀젼의 크기는 
10.7 ± 1.6 nm 로 관찰되었으며, 투과전자현미경 (TEM)을 통해 성상을 
확인하였다. 체내 약물동태학적 연구에서, DN200428 이 봉입 된 SMEDDS 
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제형에서 DMSO:PEG400 (8:92)로 단순히 녹인 용액에 비해 2 배 이상 
높아진 상대 경구 생체이용률이 관찰되었다. 결론적으로, DN200428 의 





































































































































































































































































X1 : Amount of oil (Capmul MCM EP) 5 15
X2 : Amount of surfactant (Tween 20) 55 75




















X1 : Amount of oil (Capmul MCM EP) 5 15
X2 : Amount of surfactant (Tween 20) 55 75














(%; X1) (%; X2) (%; X3)
1 5 65 30
2 5 70 25
3 5 75 20
4 5 75 20
5 5 60 35
6 5 60 35
7 10 75 15
8 10 75 15
9 10 65 25
10 10 60 30
11 10 55 30
12 15 55 30
13 15 60 25
14 15 65 20
15 15 70 15
16 15 70 15
















No. (%; X1) (%; X2) (%; X3) (µg/mL; Y1) (mg/mL; Y2)
1 5 65 30 1.799 ± 0.01 6.763 ± 0.04
2 5 70 25 1.893 ± 0.07 6.427 ± 0.07
3 5 75 20 2.142 ± 0.10 6.229 ± 0.05
4 5 75 20 2.195 ± 0.11 6.671 ± 0.06
5 5 60 35 1.576 ± 0.05 6.906 ± 0.10
6 5 60 35 1.620 ± 0.02 6.671 ± 0.11
7 10 75 15 2.155 ± 0.11 5.655 ± 0.04
8 10 75 15 2.048 ± 0.14 5.527 ± 0.11
9 10 65 25 1.610 ± 0.08 5.736 ± 0.07
10 10 60 30 1.531 ± 0.01 5.893 ± 0.10
11 15 55 30 1.402 ± 0.10 5.037 ± 0.04
12 15 55 30 1.419 ± 0.10 5.058 ± 0.06
13 15 60 25 1.613 ± 0.06 4.985 ± 0.02
14 15 65 20 1.597 ± 0.07 5.018 ± 0.05
15 15 70 15 1.819 ± 0.06 4.754 ± 0.01
16 15 70 15 1.808 ± 0.08 4.868 ± 0.02
Composition and observed responses from randomized runs in the D‐optimal mixture design
II. Research plan: Step 5















Linear < 0.0001 0.6740 0.07 0.9379 0.9283 0.9112 ‐ ‐
Quadratic 0.0487 0.1596 0.06 0.9708 0.9561 0.9327 22.120 Suggested
Special cubic 0.6748 0.1201 0.06 0.9714 0.9523 0.9118 ‐ ‐
Cubic 0.0189 0.7338 0.04 0.9908 0.9803 0.9572 ‐ Aliased
Solubilized capacity (SC) (mg/mL; Y2)
Linear < 0.0001 0.9660 0.12 0.9779 0.9745 0.9652 37.055 Suggested
Quadratic 0.8681 0.9049 0.13 0.9794 0.9690 0.9472 ‐ ‐
Special cubic 0.5842 0.8690 0.14 0.9801 0.9668 0.9383 ‐ ‐




Fitting modelII. Research plan: Step 5
Construction of Equations Based On The Results







Y 1.80	X 2.47	X 1.52	X 1.57	X X 0.84	X X 0.66	X X




II. Research plan: Step 5
Predicted responsesOptimized SMEDDS formulation




Y 1.80	X 2.47	X 1.52 X 1.57	X X 0.84	X X 0.66 X X Y 2.47 X 6.36	X 6.86	X
Contour Plot for Desirability






II. Research plan: Step 5
Response Predicted value Experimental value Prediction error (%)
Droplet size (nm) ‐ 10.7 ± 1.6 ‐
Polydispersity index ‐ 0.006 ± 0.0 ‐
DIL (µg/mL; Y1) 2.17 2.34 ± 0.21 7.26












II. Research plan: Step 5





Optimized SMEDDS (without water)





















































































































































BA (%) ‐ 6.78 3.87 11.04 12.46
CL (mL/min/kg) 21.66 ± 2.61
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